Loading...
Loading...
- Eli Lilly And Co LLY has posted Q3 sales of $6.77 billion, beating the consensus of $5.70 billion and increasing 18% Y/Y.
- Higher sales were driven by a 17% increase in volume and a 1% increase due to the favorable impact of foreign exchange rates. Net realized prices were essentially flat.
- Key growth products included Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Tyvyt, Retevmo, and Cyramza.
- Revenue from COVID-19 therapies during the quarter reached $423.5 million.
- The gross margin was 78.9%, an increase of 2.0 percentage points. Adjusted operating margin reached 30.5%.
- Adjusted EPS increased 38% Y/Y to $1.94, sharply ahead of the consensus of $1.68.
- FY21 guidance: Eli Lilly anticipates revenue of $27.2 billion - $27.6 billion, better than $26.8 billion - $27.4 billion previously expected, reflecting additional revenue from COVID-19 antibodies and the core business.
- It forecasts revenue from COVID-19 therapies of $1.3 billion, higher than $1.0 billion - $1.1 billion, anticipated earlier.
- Lilly sees adjusted EPS $7.95 - $8.05, better than the prior guidance of $7.80 - $8.00, versus the consensus of $6.80.
- Related: AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody.
- Price Action: LLY shares are up 0.18% at $245.5 during the premarket session on the last check Tuesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in